Vor Biopharma Inc.
VOR
$7.53
-$0.15-1.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.37M | 21.65M | 26.46M | 27.88M | 29.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 337.29M | 336.67M | 122.15M | 121.19M | 118.00M |
| Operating Income | -337.29M | -336.67M | -122.15M | -121.19M | -118.00M |
| Income Before Tax | -2.45B | -1.66B | -118.60M | -116.91M | -112.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.45K | -1.66K | -118.60 | -116.91 | -112.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.45B | -1.66B | -118.60M | -116.91M | -112.46M |
| EBIT | -337.29M | -336.67M | -122.15M | -121.19M | -118.00M |
| EBITDA | -333.56M | -332.09M | -118.74M | -117.66M | -114.44M |
| EPS Basic | -386.85 | -273.27 | -30.18 | -34.03 | -33.00 |
| Normalized Basic EPS | -238.81 | -167.73 | -18.86 | -21.27 | -20.62 |
| EPS Diluted | -386.85 | -273.27 | -30.18 | -34.03 | -33.00 |
| Normalized Diluted EPS | -238.81 | -167.73 | -18.86 | -21.27 | -20.62 |
| Average Basic Shares Outstanding | 22.69M | 19.43M | 16.58M | 13.74M | 13.63M |
| Average Diluted Shares Outstanding | 22.69M | 19.43M | 16.58M | 13.74M | 13.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |